|
|
|
Volumn 5, Issue 1, 2004, Pages 82-89
|
|
Pregabalin Pfizer
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 AMINOBUTYRIC ACID DERIVATIVE;
ALPRAZOLAM;
AMITRIPTYLINE;
BENZODIAZEPINE DERIVATIVE;
CALCIUM CHANNEL;
GABAPENTIN;
INSULIN;
LORAZEPAM;
MORPHINE;
NAPROXEN;
ORAL ANTIDIABETIC AGENT;
PREGABALIN;
VENLAFAXINE;
VIGABATRIN;
ANALGESIC ACTIVITY;
ANTICONVULSANT ACTIVITY;
ANTIINFLAMMATORY ACTIVITY;
AREA UNDER THE CURVE;
ARTICLE;
ATAXIA;
CENTRAL NERVOUS SYSTEM DISEASE;
CLINICAL TRIAL;
DIABETIC NEUROPATHY;
DIZZINESS;
DOSE KIDNEY FUNCTION RELATION;
DRUG ABSORPTION;
DRUG APPROVAL;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG ELIMINATION;
DRUG FECES LEVEL;
DRUG HALF LIFE;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG POTENCY;
DRUG POTENTIATION;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG TOXICITY;
DRUG URINE LEVEL;
EPILEPSY;
EUROPE;
FIBROMYALGIA;
GENERALIZED ANXIETY DISORDER;
HUMAN;
MOOD DISORDER;
MYALGIA;
NEUROPATHIC PAIN;
NONHUMAN;
PSYCHOPATHY;
SEDATION;
SIDE EFFECT;
SOMNOLENCE;
STRUCTURE ACTIVITY RELATION;
TRANQUILIZING ACTIVITY;
WITHDRAWAL SYNDROME;
ANALGESICS, NON-NARCOTIC;
ANIMALS;
ANTICONVULSANTS;
ANXIETY DISORDERS;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
GAMMA-AMINOBUTYRIC ACID;
HUMANS;
PAIN;
SEIZURES;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
|
EID: 2342419052
PISSN: 14724472
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (32)
|
|
References (0)
|
